Adagrasib – Uses, Dosage, Side Effects, Interaction Adagrasib is an orally available, small-molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division, and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis. Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.[rx] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding pocket.[rx] Adagrasib targets KRASG12C, one of the most common KRAS mutations, at the cysteine 12 residue and inhibits KRAS-dependent signalling. In a phase I/IB clinical study that included patients with KRASG12C-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. The phase II of the same study showed that in patients with KRASG12C-mutated non-small-cell lung cancer (NSCLC), adagrasib was efficient without new safety signals.[rx] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRASG12C–positive NSCLC.[rx] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRASG12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy. Adagrasib joins sotorasib as another KRASG12C inhibitor approved by the FDA.[rx] Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding pocket. Adagrasib targets KRASG12C, one of the most common KRAS mutations, at the cysteine 12 residue and inhibits KRAS-dependent signaling. In phase I/IB clinical study that included patients with KRASG12C-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. Phase II of the same study showed that in patients with KRASG12C-mutated non-small-cell lung cancer (NSCLC), adagrasib was efficient without new safety signals. In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRASG12C–positive NSCLC. In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRASG12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy. Adagrasib joins [sotorasib] as another KRASG12C inhibitor approved by the FDA. Mechanism of Action In normal cells, KRAS is activated by binding to guanosine triphosphate (GTP), and this promotes the activation of the MAP kinase pathway and intracellular signal transduction. When GTP is hydrolyzed to guanosine diphosphate (GDP), KRAS is inactivated. This mechanism works as an “on”/”off” system that regulates cell growth. The substitution of Gly12 by cysteine in KRAS (KRASG12C) impairs GTP hydrolysis and maintains KRAS in its active form. Therefore, the presence of this mutation leads to uncontrolled cellular proliferation and growth, as well as malignant transformation. Adagrasib is a covalent inhibitor of KRASG12C that irreversibly and selectively binds and locks KRASG12C in its inactive, guanosine diphosphate–bound state. Therefore, the use of adagrasib inhibits tumor cell growth and viability in cancers with KRASG12C mutations with minimal off-target activity. The exposure-response relationship and pharmacodynamic response time course of adagrasib have not been elucidated. The use of adagrasib can cause QTc interval prolongation. The increase in QTc is concentration-dependent. In patients given 600 mg of adagrasib twice daily, the mean QTcF change from baseline (ΔQTcF) was 18 ms at the mean steady-state maximum concentration. The use of adagrasib can also lead to severe gastrointestinal adverse reactions, hepatotoxicity, and interstitial lung disease/pneumonitis. Indications Adagrasib is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s). Adagrasib is a KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).[rx] Locally Advanced Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer Use in Cancer Adagrasib is approved to treat: Non-small cell lung cancer (NSCLC) that has spread and has a KRAS p.G12C mutation. It is used in adults who have received at least one other systemic therapy. Adagrasib is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients. Adagrasib is also being studied in the treatment of other types of cancer. Contraindications low amount of magnesium in the blood low amount of calcium in the blood low amount of potassium in the blood torsades de pointes, a type of abnormal heart rhythm slow heartbeat prolonged QT interval on EKG chronic heart failure abnormal EKG with QT changes from birth abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding lung tissue problem Dosage Strength: Tablets: 200 mg Recommended dosage: 600 mg orally twice daily. Swallow tablets whole with or without food. Select patients for treatment of locally advanced or metastatic NSCLC with KRAZATI based on the presence of KRAS G12C mutation in plasma or tumor specimens. If no mutation is detected in a plasma specimen, test tumor tissue. Information on FDA-approved tests for the detection of a KRAS G12C mutation is available at: https://www.fda.gov/CompanionDiagnostics Recommended Dosage The recommended dosage of KRAZATI is 600 mg orally twice daily until disease progression or unacceptable toxicity. Take KRAZATI at the same time every day with or without food. Swallow tablets whole. Do not chew, crush or split tablets. If vomiting occurs after taking KRAZATI, do not take an additional dose. Resume dosing at the next scheduled time. If a dose is inadvertently missed, it should be skipped if greater than 4 hours have elapsed from the expected dosing time. Resume dosing at the next scheduled time. Recommended dose reductions for adverse reactions are outlined in Table 1. If adverse reactions occur, a maximum of two dose reductions are permitted. Permanently discontinue KRAZATI in patients who are unable to tolerate 600 mg once daily. Side Effects The Most Common diarrhea, nausea, fatigue, vomiting, musculoskeletal pain, hepatotoxicity, renal impairment, dyspnea, edema, decreased appetite, cough, pneumonia, dizziness, constipation, abdominal pain, and QTc interval prolongation. More Common decreased lymphocytes, increased aspartate aminotransferase, decreased sodium, decreased hemoglobin, increased creatinine, decreased albumin, increased alanine aminotransferase, increased lipase, decreased platelets, decreased magnesium, and decreased potassium. Rare your skin or the white part of your eyes turns yellow (jaundice) dark or “tea-colored” urine light-colored stools (bowel movements) tiredness or weakness nausea or vomiting bleeding or bruising loss of appetite pain, aching or tenderness on the right side of your stomach area (abdomen) muscle and bone pain kidney problems swelling breathing trouble decreased appetite Drug Interaction DRUG INTERACTION Alfentanil The serum concentration of Alfentanil can be increased when it is combined with Adagrasib. Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Adagrasib. Amiodarone The serum concentration of Adagrasib can be increased when it is combined with Amiodarone. Amprenavir The serum concentration of Adagrasib can be increased when it is combined with Amprenavir. Apalutamide The serum concentration of Adagrasib can be decreased when it is combined with Apalutamide. Aprepitant The serum concentration of Aprepitant can be increased when it is combined with Adagrasib. Articaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Articaine. Atazanavir The serum concentration of Adagrasib can be increased when it is combined with Atazanavir. Atomoxetine The serum concentration of Atomoxetine can be increased when it is combined with Adagrasib. Atorvastatin The serum concentration of Atorvastatin can be increased when it is combined with Adagrasib. Avanafil The serum concentration of Avanafil can be increased when it is combined with Adagrasib. Benzocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Benzyl alcohol. Boceprevir The serum concentration of Adagrasib can be increased when it is combined with Boceprevir. Budesonide The serum concentration of Budesonide can be increased when it is combined with Adagrasib. Bupivacaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Bupivacaine. Buspirone The serum concentration of Buspirone can be increased when it is combined with Adagrasib. Butacaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Capsaicin. Carbamazepine The serum concentration of Adagrasib can be decreased when it is combined with Carbamazepine. Celecoxib The serum concentration of Celecoxib can be increased when it is combined with Adagrasib. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Cinchocaine. Clarithromycin The serum concentration of Adagrasib can be increased when it is combined with Clarithromycin. Clozapine The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Clozapine. Cobicistat The serum concentration of Adagrasib can be increased when it is combined with Cobicistat. Cocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Cocaine. Colchicine The serum concentration of Colchicine can be increased when it is combined with Adagrasib. Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Adagrasib. Curcumin The serum concentration of Adagrasib can be increased when it is combined with Curcumin. Danazol The serum concentration of Adagrasib can be increased when it is combined with Danazol. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Adagrasib. Darifenacin The serum concentration of Darifenacin can be increased when it is combined with Adagrasib. Darunavir The serum concentration of Darunavir can be increased when it is combined with Adagrasib. Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Adagrasib. Delamanid Adagrasib may increase the QTc-prolonging activities of Delamanid. Delavirdine The serum concentration of Adagrasib can be increased when it is combined with Delavirdine. Desipramine The serum concentration of Desipramine can be increased when it is combined with Adagrasib. Dexamethasone The serum concentration of Adagrasib can be decreased when it is combined with Dexamethasone. Dextromethorphan The serum concentration of Dextromethorphan can be increased when it is combined with Adagrasib. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Diphenhydramine. Dronedarone The serum concentration of Dronedarone can be increased when it is combined with Adagrasib. Dyclonine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Dyclonine. Ebastine The serum concentration of Ebastine can be increased when it is combined with Adagrasib. Econazole The serum concentration of Adagrasib can be increased when it is combined with Econazole. Efavirenz The serum concentration of Adagrasib can be increased when it is combined with Efavirenz. Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Adagrasib. Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Adagrasib. Elvitegravir The serum concentration of Adagrasib can be increased when it is combined with Elvitegravir. Encainide The serum concentration of Encainide can be increased when it is combined with Adagrasib. Entrectinib The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Entrectinib. Enzalutamide The serum concentration of Adagrasib can be decreased when it is combined with Enzalutamide. Eplerenone The serum concentration of Eplerenone can be increased when it is combined with Adagrasib. Ergotamine The serum concentration of Adagrasib can be increased when it is combined with Ergotamine. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Adagrasib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Etidocaine. Everolimus The serum concentration of Everolimus can be increased when it is combined with Adagrasib. Felodipine The serum concentration of Felodipine can be increased when it is combined with Adagrasib. Fexinidazole The risk or severity of adverse effects can be increased when Adagrasib is combined with Fexinidazole. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Adagrasib. Fosphenytoin The serum concentration of Adagrasib can be decreased when it is combined with Fosphenytoin. Glimepiride The serum concentration of Glimepiride can be increased when it is combined with Adagrasib. Haloperidol The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Haloperidol. Hydroxyzine The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Hydroxyzine. Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Adagrasib. Imipramine The serum concentration of Imipramine can be increased when it is combined with Adagrasib. Indinavir The serum concentration of Indinavir can be increased when it is combined with Adagrasib. Isavuconazole The serum concentration of Isavuconazole can be increased when it is combined with Adagrasib. Itraconazole The serum concentration of Adagrasib can be increased when it is combined with Itraconazole. Ivabradine The serum concentration of Ivabradine can be increased when it is combined with Adagrasib. Ketoconazole The serum concentration of Adagrasib can be increased when it is combined with Ketoconazole. Lefamulin Lefamulin may increase the QTc-prolonging activities of Adagrasib. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Adagrasib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Levobupivacaine. Levoketoconazole The serum concentration of Adagrasib can be increased when it is combined with Levoketoconazole. Lidocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Lidocaine. Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Adagrasib. Lonafarnib The serum concentration of Adagrasib can be increased when it is combined with Lonafarnib. Lopinavir The serum concentration of Adagrasib can be increased when it is combined with Lopinavir. Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Adagrasib. Lumacaftor The serum concentration of Adagrasib can be decreased when it is combined with Lumacaftor. Lurasidone The serum concentration of Lurasidone can be increased when it is combined with Adagrasib. Maraviroc The serum concentration of Maraviroc can be increased when it is combined with Adagrasib. Meloxicam The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Mepivacaine. Methimazole The serum concentration of Adagrasib can be increased when it is combined with Methimazole. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Adagrasib. Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Adagrasib. Midazolam The serum concentration of Midazolam can be increased when it is combined with Adagrasib. Midostaurin The serum concentration of Adagrasib can be decreased when it is combined with Midostaurin. Mitotane The serum concentration of Adagrasib can be decreased when it is combined with Mitotane. Mobocertinib The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Mobocertinib. Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Adagrasib. Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Adagrasib. Nefazodone The serum concentration of Adagrasib can be increased when it is combined with Nefazodone. Nelfinavir The serum concentration of Adagrasib can be increased when it is combined with Nelfinavir. Nilotinib The serum concentration of Adagrasib can be increased when it is combined with Nilotinib. Nisoldipine The serum concentration of Nisoldipine can be increased when it is combined with Adagrasib. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Adagrasib. Oxetacaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Oxybuprocaine. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Adagrasib. Pentobarbital The serum concentration of Adagrasib can be decreased when it is combined with Pentobarbital. Perphenazine The serum concentration of Perphenazine can be increased when it is combined with Adagrasib. Phenobarbital The serum concentration of Adagrasib can be decreased when it is combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Phenol. Phenytoin The serum concentration of Adagrasib can be decreased when it is combined with Phenytoin. Pimozide The serum concentration of Pimozide can be increased when it is combined with Adagrasib. Pitolisant Adagrasib may increase the QTc-prolonging activities of Pitolisant. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Adagrasib. Posaconazole The serum concentration of Adagrasib can be increased when it is combined with Posaconazole. Pramocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Pramocaine. Prilocaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Prilocaine. Primidone The serum concentration of Adagrasib can be decreased when it is combined with Primidone. Procaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Procaine. Propafenone The serum concentration of Propafenone can be increased when it is combined with Adagrasib. Proparacaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Propoxycaine. Propranolol The serum concentration of Propranolol can be increased when it is combined with Adagrasib. Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Adagrasib. Ribociclib The serum concentration of Adagrasib can be increased when it is combined with Ribociclib. Rifampicin The serum concentration of Adagrasib can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Adagrasib can be decreased when it is combined with Rifamycin. Rifapentine The serum concentration of Adagrasib can be decreased when it is combined with Rifapentine. Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Adagrasib. Rimexolone The serum concentration of Adagrasib can be decreased when it is combined with Rimexolone. Ritonavir The serum concentration of Adagrasib can be increased when it is combined with Ritonavir. Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Adagrasib. Ropivacaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Ropivacaine. Saquinavir The serum concentration of Saquinavir can be increased when it is combined with Adagrasib. Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Adagrasib. Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Adagrasib. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Adagrasib. St. John’s Wort The serum concentration of Adagrasib can be decreased when it is combined with St. John’s Wort. Stiripentol The serum concentration of Adagrasib can be increased when it is combined with Stiripentol. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Adagrasib. Tadalafil The serum concentration of Tadalafil can be increased when it is combined with Adagrasib. Telaprevir The serum concentration of Adagrasib can be increased when it is combined with Telaprevir. Telithromycin The serum concentration of Adagrasib can be increased when it is combined with Telithromycin. Terfenadine The serum concentration of Adagrasib can be increased when it is combined with Terfenadine. Tetracaine The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Tetracaine. Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Adagrasib. Tipranavir The serum concentration of Tipranavir can be increased when it is combined with Adagrasib. Tolbutamide The serum concentration of Tolbutamide can be increased when it is combined with Adagrasib. Tolterodine The serum concentration of Tolterodine can be increased when it is combined with Adagrasib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Adagrasib. Tramadol The serum concentration of Tramadol can be increased when it is combined with Adagrasib. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Adagrasib. Triazolam The serum concentration of Triazolam can be increased when it is combined with Adagrasib. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Adagrasib. Troleandomycin The serum concentration of Adagrasib can be increased when it is combined with Troleandomycin. Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Adagrasib. Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Adagrasib. Venlafaxine The serum concentration of Venlafaxine can be increased when it is combined with Adagrasib. Voriconazole The serum concentration of Adagrasib can be increased when it is combined with Voriconazole. Ziprasidone The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Ziprasidone. Pregnancy and Lactation FDA Pregnancy Category : Not Assign Pregnancy There are no available data on the use of KRAZATI in pregnant women. In animal reproduction studies, oral administration of adagrasib to pregnant rats and rabbits during the period of organogenesis did not cause adverse development effects or embryo-fetal lethality at exposures below the human exposure at the recommended dose of 600 mg twice daily (see DATA). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Lactation There are no data on the presence of adagrasib or its metabolites in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with KRAZATI and for 1 week after the last dose. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Adagrasib https://www.cancer.gov/about-cancer/treatment/drugs/adagrasib https://go.drugbank.com/drugs/DB15568 https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid https://www.drugs.com/history/krazati.html https://en.wikipedia.org/wiki/Adagrasib https://www.webmd.com/drugs/2/drug-185563/adagrasib-oral/details/list-contraindications http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594350/ https://www.ebi.ac.uk/chembl/g/#browse/targets https://www.chemicalprobes.org/mrtx849 https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10888 https://www.guidetopharmacology.org/targets.jsp https://idrblab.net/ttd/data/drug/details/DUQV41 https://www.nlm.nih.gov/copyright.html https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=2326521713 https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus https://www.drugbank.ca/legal/terms_of_use https://www.drugbank.ca/drugs/DB15568 https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals https://www.fda.gov/about-fda/about-website/website-policies#linking https://gsrs.ncats.nih.gov/ginas/app/beta/substances/8EOO6HQF8Y https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ https://www.nlm.nih.gov/copyright.html https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ADAGRASIB https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C157493 https://ncit.nci.nih.gov Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/461504998 EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=43064044-512220162 https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ https://www.whocc.no/atc_ddd_index/ https://pubchem.ncbi.nlm.nih.gov https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html https://www.ncbi.nlm.nih.gov/mesh/2100393 http://www.nlm.nih.gov/mesh/meshhome.html https://www.ncbi.nlm.nih.gov/mesh/68000970 https://pubchem.ncbi.nlm.nih.gov/substance/397275154 References